Who are VLI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VIN, Paclitaxel protein bound, Paclitaxel (Pac), Paclitaxel injection, ''albendazole'' and ''ivermectin'', Placebo plus Docetaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vli.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

VLI — Competitive Intelligence Brief

VLI (VLI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vinca alkaloid. Area: Oncology.

marketed Vinca alkaloid β-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

VLI (VLI) — Spectrum Pharmaceuticals, Inc. VLI is a vinca alkaloid that inhibits microtubule assembly by binding to tubulin, disrupting cell division and causing cell death in rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VLI TARGET	VLI	Spectrum Pharmaceuticals, Inc	marketed	Vinca alkaloid	β-tubulin
VIN	VIN	Italian Sarcoma Group	marketed	Vinca alkaloid; microtubule inhibitor	β-tubulin
Paclitaxel protein bound	Paclitaxel protein bound	Barts & The London NHS Trust	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin
''albendazole'' and ''ivermectin''	''albendazole'' and ''ivermectin''	Centre d'Appui à la lutte contre la Maladie	marketed	Antihelmintic/Antiparasitic agents	β-tubulin (albendazole); glutamate-gated chloride channels (ivermectin)
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vinca alkaloid class)

Assistance Publique Hopitaux De Marseille · 1 drug in this class
Spectrum Pharmaceuticals, Inc · 1 drug in this class
Universität des Saarlandes · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VLI — Competitive Intelligence Brief. https://druglandscape.com/ci/vli. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab